ArticleFrontiers in pharmacology2026
Physiologically based pharmacokinetic modeling of tafenoquine and evaluation of transporter-mediated drug-drug interactions.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model of tafenoquine (TQ), a new drug for the radical cure of Methods: A whole-body PBPK model was built using PK-Sim® to simulate 100 adults aged 19-53 years weighing 51-108 kg. Hepatic clearance was incorporated into the model. Literature data on the oral administration of TQ were used to verify the model. The qualified model was used to simulate co-administration with metformin (MTF), an OCT2 and MATE1 substrate, and assess drug-drug interactions. Results and Discussion: The PBPK model presented a good descriptive and predictive performance for plasma concentration-time profiles. Quantitative measures of the model performance fell within the 2-fold acceptance criteria when predictions were compared to observed values. Co-administration of TQ with MTF presented no alteration of MTF's exposure. Model simulations suggest that there is no significant interaction between TQ and substrates of OCT2/MATE1, such as MTF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.